Lymphoseek for Diagnosis and Investigation User Reviews
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about Lymphoseek (tilmanocept)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: radiologic conjugating agents
- Breastfeeding
"Conduced first exploratory use in June, 2013 indication cutaneous melanoma, Breslow/3mm. Tilmanocept was well received by the patient with no local. Clearance delay provision <20 min. SLN discovery total <4 min/2 SLN/Path."